Home > About Us

About Shire

We're with you.

Longer than any other manufacturer, Shire* has been a reliable and consistent supplier of Ig treatment.1

Through Growth and Transition

Shire's* investments in plasma treatment processing have grown from $614 million to $1.2 billion in recent years, and Shire is committed to continued investment in the future.1

With 60 state-of-the-art plasma collection centers, Shire collects nearly 4 million liters of source plasma each year to meet the needs of those who rely on plasma-based treatment.2,3 Shire also has the largest fractionation capacity among all plasma manufacturers and plans to build a new facility that will add up to 3 million liters of fractionation capacity annually when fully functional.1

With Education and Support

Shire offers unprecedented support and a wealth of educational resources, created with the help of patients, caregivers, and healthcare professionals from the community. All support is offered without charge to patients and caregivers, regardless of treatment.

Learn more about MyIgSource.

Yesterday, Today, and Tomorrow

Shire plc* became a leader in plasma fractionation in 1941 and is the only company that has been continuously processing IVIG for 25 years.4 Our aim is to provide the highest quality products and programs that advance patient care globally and enable the achievement of outcomes through innovation, science, and technology.

*Shire plc bought Baxalta Incorporated in 2016. Baxalta Incorporated was formerly the BioScience Division at Baxter International Inc. and continues to provide those same treatments and products.

References: 1. Baxter International Inc. 2012 Annual Report. 2. BioLife Press Kit. http://biolifeplasma.com/downloads/biolife-press-kit.pdf. Accessed June 24, 2013. 3. Data on file (BioLife Directory). Baxter Healthcare Corporation. 4. Marketing Research Bureau. The plasma proteins market in the United States 2011. Published June 2012.

You are now leaving GAMMAGARD.com

Shire is not responsible for the privacy policy, the content or the accuracy of any web site accessed through a link on the GAMMAGARD.com site. A link to other web sites does not constitute an endorsement of Shire of the linked site, its products or services.

The browser window or tab for GAMMAGARD.com will remain open underneath the new browser window or tab. To return to GAMMAGARD.com at any time, close this tab or window.

Return to

Terms and Conditions

Patient instructions

  1. By using this coupon, you are certifying that:
  2. 1) You meet the eligibility criteria and have read and agree to the terms and conditions of this manufacturer coupon program;
  3. 2) You will not, at any time, submit any costs for the product dispensed pursuant to this coupon to any government healthcare program for reimbursement;
  4. 3) You are permitting your personal information, including name, address, phone number, email address, and information related to health insurance and treatment, to be shared with Shire and companies working with Shire for the purpose of administering this program; and
  5. 4) You will notify your health insurance provider or other third-party payer of the use of this coupon if required to do so.
  6. If your insurance situation changes it is your responsibility to notify Shire's MyIgCoPayCard program.
  7. For questions about this program, patients and caregivers can call MyIgSource at (855) 250-5111.

Pharmacy instructions

  1. By submitting a claim for reimbursement pursuant to this manufacturer coupon program, the Pharmacy represents and warrants that:
  2. 1) It has dispensed GAMMAGARD LIQUID treatment to an eligible patient and in accordance with the terms and conditions of this program and the accompanying prescription;
  3. 2) Its participation in this program is consistent with all applicable laws and any obligations, including its contract with the applicable payer;
  4. 3) If the patient's insurance situation changes, it will notify Shire immediately by contacting the MyIgCoPayCard program;
  5. 4) It will report coupon assistance received to payers if so required; and
  6. 5) The entire benefit amount received will go to eligible expenses and it will not retain any portion of the benefit as payment to it for administration or ineligible expenses.
  7. For questions regarding processing, claim transmission, patient eligibility, or other issues, pharmacists can call the MyIgCoPayCard program directly at (855) 217-1615.